Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Jacobs & Co. CA

Jacobs & Co. CA reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 29.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,052 shares of the medical instruments supplier’s stock after selling 12,760 shares during the period. Jacobs & Co. CA’s holdings in Becton, Dickinson and Company were worth $7,044,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of BDX. Livelsberger Financial Advisory purchased a new position in Becton, Dickinson and Company in the third quarter worth approximately $26,000. Ashton Thomas Securities LLC purchased a new position in Becton, Dickinson and Company in the third quarter worth approximately $33,000. Tompkins Financial Corp grew its position in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares during the period. Sound Income Strategies LLC grew its position in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares during the period. Finally, Abound Wealth Management grew its position in Becton, Dickinson and Company by 96.0% in the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after acquiring an additional 96 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 2,838 shares of the company’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $223.33, for a total transaction of $633,810.54. Following the completion of the sale, the executive vice president now directly owns 6,141 shares in the company, valued at $1,371,469.53. This represents a 31.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Roland Goette sold 638 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the sale, the executive vice president now owns 14,217 shares of the company’s stock, valued at $3,113,949.51. The trade was a 4.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 8,747 shares of company stock worth $1,949,520 in the last ninety days. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE:BDX traded up $0.59 during midday trading on Friday, reaching $235.02. The stock had a trading volume of 1,590,186 shares, compared to its average volume of 1,723,689. The firm has a fifty day simple moving average of $226.94 and a two-hundred day simple moving average of $232.47. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $248.42. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The stock has a market cap of $68.16 billion, a P/E ratio of 39.57, a P/E/G ratio of 1.64 and a beta of 0.39.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter last year, the company earned $3.42 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 6.9% compared to the same quarter last year. On average, equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th were issued a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 1.77%. The ex-dividend date was Monday, December 9th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is 70.03%.

Analyst Ratings Changes

A number of research analysts have commented on the company. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Finally, Evercore ISI upped their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $283.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.